Add like
Add dislike
Add to saved papers

Sharp recanalization with transseptal needle for unsuccessful standard recanalization of chronic thoracic central vein occlusion in hemodialysis patients.

BACKGROUND: Many cases of chronic thoracic central vein occlusion (CVO) fail to recanalize using the standard conventional guidewire technique. This study aims to present the outcomes of sharp recanalization with a transseptal needle in chronic thoracic CVO.

METHODS: This retrospective study involved 22 hemodialysis patients who developed clinical signs and symptoms of CVO, had unsuccessful conventional endovascular treatment using guidewire, and underwent sharp recanalization with a transseptal needle from January 2018 to December 2021. Demographic information of patients, technical success rate, and complications were kept. Post-intervention primary patency rate was examined using survival regression.

RESULTS: Thirteen men and nine women were enrolled with a median age of 50 years (range: 30-83 years). The most common site of thoracic CVO was the right brachiocephalic vein (21 patients). The average length of occlusion was 2.5 cm (range: 1-4.4 cm). Technical success rate was 90.9% (20 patients). Major complications occurred in three instances, including severe hemothorax and pulmonary edema. The median post-intervention primary patency between balloon angioplasty alone and primary stenting was 2.1 and 8.0 months ( p  = 0.015). Post-intervention primary patency rates at 6 and 12 months in the group receiving balloon angioplasty alone versus primary stenting were 33.3% and 0% versus 70.6% and 29.4% ( p  = 0.013).

CONCLUSION: Sharp recanalization with a transseptal needle is successful in chronic thoracic CVO cases that fail with conventional recanalization. Primary stenting in this CVO lesion shows a greater primary patency compared to balloon angioplasty alone.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app